Abstract:Abstract The gasdermins (GSDM) are a family of homologous pore-forming proteins that cause pyroptosis, an inflammatory death associated with loss of cell membrane integrity and release of inflammatory mediators. Gasdermin E (GSDME, also known as DFNA5) as the most ancient member of the GSDM family has been implicated as a tumor suppressor. GSDME is epigenetically inactivated by promoter DNA methylation in a number of cancers and mutated in some other cancers. Worse 5-year survival and an increase in lymph node metastases are associated with reduced GSDME in breast cancer. During classic apoptosis, caspase-3 activates GSDME by cleaving after Asp270. GSDME activation converts noninflammatory apoptotic death to an inflammatory pyroptotic death. This switch could have a profound effect on the ability of tumor cells to survive intrinsic cellular stresses and extrinsic challenges, such as ER stress, chemotherapy drugs, or immune attack by cytotoxic lymphocytes. Here we show reduced GSDME function of 7 of 8 tested cancer-associated mutations. By manipulating GSDME expression in diverse cancer cell lines, we show that Gsdme knockout in GSDME-expressing tumors enhances, while ectopic expression in Gsdme-repressed tumors inhibits, tumor growth. Our data demonstrate that GSDME tumor-suppressive effect is cell-extrinsic, mediated by cytotoxic lymphocyte killing and abrogated in perforin-deficient mice or mice lacking lymphocytes. Tumor suppression depended on GSDME’s ability to form cell membrane pores that cause inflammatory pyroptosis, since it was completely blocked by mutating the GSDME cleavage site for pore formation. Using different cancer models, we further show that GSDME expression enhances tumor-associated macrophage phagocytosis and the number and functions of tumor-infiltrating NK and CD8+ T lymphocytes. Importantly, we identify that immune killer cells could activate GSDME-mediated pyroptosis independently of caspase activation, when killer cell cytotoxic protease granzyme B directly cleaves and activates GSDME at the same site as caspase-3 (Asp270). Therefore, immune killer cells induce pyroptosis in target GSDME-expressing cancer cells, creating an inflammatory tumor microenvironment that further facilities immune cell tumor infiltration and forms a positive feedback loop. Thus, GSDME suppresses tumor growth by activating antitumor immunity. Citation Format: Zhibin Zhang, Ying Zhang, Shiyu Xia, Qing Kong, Shunying Li, Xing Liu, Caroline Junqueira, James Ansara, Satyaki Sengupta, Yandan Yao, Hao Wu, Judy Lieberman. Gasdermin E suppresses tumor growth by activating antitumor immunity [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2019 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(3 Suppl):Abstract nr B58.

Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis‐Independent Mechanism

Gasdermin C as a potential prognostic biomarker and its correlation with immune infiltration in pancreatic ductal adenocarcinoma.

Gasdermin-mediated Pyroptosis Confers Anticancer Immunity

Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade

Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1–mucin pathway

The Expression Profile of Gasdermin C-related Genes Predicts the Prognosis and Immunotherapy Response of Pancreatic Adenocarcinoma.

Chemotherapeutic Drugs-Induced Pyroptosis Mediated by Gasdermin E Promotes the Progression and Chemoresistance of Pancreatic Cancer

A Pan-Cancer Analysis of Molecular Characteristics and Oncogenic Role of Gasdermins

The Critical Roles of Activated Stellate Cells-Mediated Paracrine Signaling, Metabolism and Onco-Immunology in Pancreatic Ductal Adenocarcinoma

Downregulation of GSDMD Attenuates Tumor Proliferation Via the Intrinsic Mitochondrial Apoptotic Pathway and Inhibition of EGFR/Akt Signaling and Predicts a Good Prognosis in Non‑small Cell Lung Cancer.

Activated K‐Ras and INK4a/Arf Deficiency Promote Aggressiveness of Pancreatic Cancer by Induction of EMT Consistent with Cancer Stem Cell Phenotype

Gasdermin D Plays an Oncogenic Role in Glioma and Correlates to an Immunosuppressive Microenvironment

Abstract B58: Gasdermin E Suppresses Tumor Growth by Activating Antitumor Immunity

A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer

Prognostic and Immunological Role of Gasdermin E in Pan-Cancer Analysis

Abstract A022: Gasdermin E Suppresses Tumor Growth by Activating Antitumor Immunity

Pan-cancer Analysis Reveals the Expression, Genetic Alteration and Prognosis of Pyroptosis Key Gene GSDMD

SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation

Gasdermin C Sensitizes Tumor Cells to PARP Inhibitor Therapy in Cancer Models.

Gasdermin E benefits CD8+T cell mediated anti-immunity through mitochondrial damage to activate cGAS-STING-interferonβ axis in colorectal cancer

The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells